Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment
Primary Purpose
Hypogonadism
Status
Completed
Phase
Phase 4
Locations
Turkey
Study Type
Interventional
Intervention
Testosterone
Sponsored by
About this trial
This is an interventional screening trial for Hypogonadism focused on measuring visceral adiposity index, triglycerides / hdl cholesterol ratio, testosterone
Eligibility Criteria
Inclusion Criteria:
- Men
- Congenital hypogonadism
- Treatment Naive
Exclusion Criteria:
- Previous history of androgen replacement
- Hypertension
- Diabetes mellitus
Sites / Locations
- Gulhane School of Medicine
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
testosterone
Arm Description
testosterone gel per day for 6 months testosterone 250 mg injection per 3-4 weeks for 6 months
Outcomes
Primary Outcome Measures
time to change of visceral adiposity index with testosteron replacement
time to change of TG/HDL cholesterol ratio with testosteron replacement
Secondary Outcome Measures
Full Information
NCT ID
NCT02111434
First Posted
April 5, 2014
Last Updated
April 10, 2014
Sponsor
Gulhane School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02111434
Brief Title
Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment
Official Title
Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism
Study Type
Interventional
2. Study Status
Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
July 2013 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
April 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Gulhane School of Medicine
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study is designed to answer the following questions:
What is the levels of visceral adiposity index and Triglycerides/HDL cholesterol ratio in hypogonadism?
What is the effect of testosterone replacement on the visceral adiposity index and Triglycerides/HDL cholesterol ratio?
Detailed Description
This is a retrospective design, which is performed by investigating the registrations of patients with hypogonadotrophic hypogonadism between the years 2007-2010.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypogonadism
Keywords
visceral adiposity index, triglycerides / hdl cholesterol ratio, testosterone
7. Study Design
Primary Purpose
Screening
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Actual)
8. Arms, Groups, and Interventions
Arm Title
testosterone
Arm Type
Experimental
Arm Description
testosterone gel per day for 6 months testosterone 250 mg injection per 3-4 weeks for 6 months
Intervention Type
Drug
Intervention Name(s)
Testosterone
Other Intervention Name(s)
sustanon 250 mg
Intervention Description
Testosterone 250 mg injection per 3-4 weeks for 6 months
Primary Outcome Measure Information:
Title
time to change of visceral adiposity index with testosteron replacement
Time Frame
baseline and 6 months
Title
time to change of TG/HDL cholesterol ratio with testosteron replacement
Time Frame
baseline and 6 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
26 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Men
Congenital hypogonadism
Treatment Naive
Exclusion Criteria:
Previous history of androgen replacement
Hypertension
Diabetes mellitus
Facility Information:
Facility Name
Gulhane School of Medicine
City
Ankara
ZIP/Postal Code
06018
Country
Turkey
12. IPD Sharing Statement
Learn more about this trial
Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment
We'll reach out to this number within 24 hrs